* history of hypersensitivity to colchicine * pregnancy or breastfeeding women. * patients with severe renal impairment (creatinine clearance (ccl) \<30 ml / min) * patients with severe hepatic impairment (ast or alt\> 5 times the normal limits in international units (uln) * patients with blood dyscrasias, neutrophils \<1.000 / mmc or platelets \<50.000 / mmc * patients with history of severe cardiac insufficiency * patients with history of pulmonary fibrosis * severe diarrhoea or bowel diverticulitis, or perforation * patients who cannot take oral therapy * patients already in icu or requiring mechanical ventilation * patients already enrolled in other clinical trials * patients with taking p-glycoprotein inhibitor (e.g. ciclosporin, verapamil or quinidine) or a cyp3a4 inhibitor (e.g. ritonavir, remdesivir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) or tocilizumab

* history of hypersensitivity to colchicine * pregnancy or breastfeeding women. * patients with severe renal impairment (creatinine clearance (ccl) \<30 ml / min) * patients with severe hepatic impairment (ast or alt\> 5 times the normal limits in international units (uln) * patients with blood dyscrasias, neutrophils \<1.000 / mmc or platelets \<50.000 / mmc * patients with history of severe cardiac insufficiency * patients with history of pulmonary fibrosis * severe diarrhoea or bowel diverticulitis, or perforation * patients who cannot take oral therapy * patients already in icu or requiring mechanical ventilation * patients already enrolled in other clinical trials * patients with taking p-glycoprotein inhibitor (e.g. ciclosporin, verapamil or quinidine) or a cyp3a4 inhibitor (e.g. ritonavir, remdesivir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) or tocilizumab

- history of hypersensitivity to colchicine - pregnancy or breastfeeding women. - patients with severe renal impairment (creatinine clearance (ccl) <30 ml / min) - patients with severe hepatic impairment (ast or alt> 5 times the normal limits in international units (uln) - patients with blood dyscrasias, neutrophils <1.000 / mmc or platelets <50.000 / mmc - patients with history of severe cardiac insufficiency - patients with history of pulmonary fibrosis - severe diarrhoea or bowel diverticulitis, or perforation - patients who cannot take oral therapy - patients already in icu or requiring mechanical ventilation - patients already enrolled in other clinical trials - patients with taking p-glycoprotein inhibitor (e.g. ciclosporin, verapamil or quinidine) or a cyp3a4 inhibitor (e.g. ritonavir, remdesivir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) or tocilizumab

- history of hypersensitivity to colchicine - pregnancy or breastfeeding women. - patients with severe renal impairment (creatinine clearance (ccl) <30 ml / min) - patients with severe hepatic impairment (ast or alt> 5 times the normal limits in international units (uln) - patients with blood dyscrasias, neutrophils <1.000 / mmc or platelets <50.000 / mmc - patients with history of severe cardiac insufficiency - patients with history of pulmonary fibrosis - severe diarrhoea or bowel diverticulitis, or perforation - patients who cannot take oral therapy - patients already in icu or requiring mechanical ventilation - patients already enrolled in other clinical trials - patients with taking p-glycoprotein inhibitor (e.g. ciclosporin, verapamil or quinidine) or a cyp3a4 inhibitor (e.g. ritonavir, remdesivir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) or tocilizumab